Ulcerative colitis and diabetes generics launched in US

Generics/News | Posted 31/08/2018 post-comment0 Post your comment

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 9 July 2018 that it had launched generic budesonide extended-release tablets (9 mg) in the US. Then on 25 July 2018, Sun Pharmaceutical Industries (Sun Pharma), one of India’s largest pharmaceutical manufacturers, announced that it had launched generic metformin extended-release tablets (500 and 1,000 mg) in the US.


Teva’s budesonide tablets are a generic drug alternative to Uceris (budesonide), which is manufactured by Salix Pharmaceuticals. The drug is a glucocorticosteroid indicated for remission in patients with active mild-to-moderate ulcerative colitis.

This is the second ulcerative colitis generic to be launched by Teva recently. The company launched generic mesalamine delayed-release tablets (1.2 g) in the US in March 2018 [1].

This latest launch ‘signals an important addition to Teva’s portfolio’, according to Brendan O’Grady, head of Teva North America Commercial.

Uceris had annual sales of approximately US$196 million in the US as of May 2018.

Sun Pharma’s generic metformin tablets are a therapeutic alternative to Glumetza (metaformin), which is manufactured by Santarus. Metaformin is indicated as an adjunct to diet and exercise in type 2 diabetes. It is the first-line medication for the treatment of type 2 diabetes.

Glumetza had sales of US$443 million for the 12 months ending April 2018, according to IQVIA.

Related article
Launches, approvals and court cases for Sun Pharma

1. GaBI Online - Generics and Biosimilars Initiative. Teva launches ulcerative colitis generic in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Aug 31]. Available from: www.gabionline.net/Generics/News/Teva-launches-ulcerative-colitis-generic-in-the-US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Sun Pharma, Teva

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010